The objective of this study was to determine whether screening for prostate cancer (PC) reduces PC mortality and, if so, whether the required criteria to be introduced as a population-based screening program are satisfied. A literature review was conducted through electronic scientific databases. The screening tests, that is, PSA and digital rectal examination, have limited sensitivity and specificity for detecting PC; screening produces a beneficial stage shift and reduces PC mortality. Nevertheless, PC screening causes a large increase in the cumulative incidence, and the understanding of the economic cost and quality-of-life parameters are limited. PC screening cannot be justified yet in the context of a public health policy.
Introduction
Prostate cancer (PC) is the most common diagnosed malignancy and the third leading cause of death from cancer in men in Western countries (after lung and colorectal cancer). 1, 2 The lifetime risk of a PC diagnosis is 15.8% for men in the United States 3 and 8% for men in the United Kingdom. 4 The lifetime risk of dying from PC is low relative to the lifetime risk of a PC diagnosis, that is, 2.8% in the United States and 4% in the United Kingdom. [1] [2] [3] [4] Overall, these incidence and mortality rates make PC of undeniable public health relevance. 5 Secondary prevention through screening would be an appealing option for PC. 6 This review aims to present the evidence available on the efficacy of screening asymptomatic men for PC. Furthermore, it summarized the available data regarding the impact of PC screening on quality of life and cost effectiveness to address the hypothesis of whether screening for PC fulfils the criteria to be introduced as a population-based screening program.
Evidence acquisition

Literature search
A MEDLINE search was performed using the terms 'prostate cancer' and 'screening' with other relevant keywords. Randomized controlled trials of screening versus no screening for PC were included. Studies with inadequate randomization were excluded. Studies that evaluated the complications, and the sensitivity and specificity of the screening test used, were eligible for this review. Furthermore, results were summarized from the corresponding screening trials for breast, lung, colorectal and cervical cancer. The searches were limited to English-language articles.
Screening for cancer
The objective of screening is to identify a disease at a stage in its natural history in which treatment can be applied to prevent death or suffering. 6 Screening aims to avoid deaths caused by cancer by preventing the development of advanced disease. Therefore, effective treatment of early-staged disease is essential to attain the aims of screening. Although screening may lead to an earlier diagnosis, screening tests will not always benefit the person being screened; overdetection (detected cancers that would not have been diagnosed in the absence of screening) with potential resultant of overtreatment (treatment of cancers that would not have been diagnosed in the absence of screening), increased costs, side effects and complications are potential adverse effects of screening. 6, 7 The final end point of a cancer screening trial is cancer-specific mortality. However, more criteria need to be fulfilled before screening can be adopted in a public health program. A total of 10 World Health Organization criteria for appraising the validity of a screening program were developed by Wilson and Jungner 8 ( Table 1) . These criteria were listed in 1968 and are still upheld today as 'classic' and 'the gold standard' of screening assessment. 9 Nevertheless, these criteria have been discussed to be too vague or theoretical, and an exchange of views regarding screening policies has occurred over the last few decades. 10, 11 This has resulted in several adoptions to the classic criteria, which have emerged in 10 new criteria ( Table 2 ). The majority of the more recent criteria overlap with the classic criteria, particularly with regard to screening for health conditions at an early stage, in which there exist effective interventions to improve outcomes compared with clinical care. Finally, many Western European countries have their own updated legal regulations on mass screening.
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Screening tests for PC
The main tool in screening for PC is the PSA test. PSA is a human protein that is secreted by prostate epithelial cells. 16, 17 The PSA test seems to be acceptable to the population as a screening procedure as the participation and adherence to screening in subsequent screening rounds is overall high. 18 PSA is a specific organ marker, but not strictly a tumor marker, as prostatitis and BPH can also increase the serum PSA. 19, 20 In part because of this, no clear PSA threshold level exists for the detection of PC. 21 Thompson et al. 22 demonstrated this in a study in which men with a PSA p3.0 ng ml À1 and a normal digital rectal examination (DRE) were randomized to an antiandrogen and placebo. After 7 years, in all men with a PSA o4.0 ng ml À1 and a normal DRE, biopsies were performed and in 15% of these men PC was detected.
In 15% of these PCs, a tumor with a Gleason score X7 was detected. 22 According to these study results, a physician who would like an 80% confidence rate in not missing a PC, should apply a PSA cutoff value of 1.1 ng ml À1 as an indication for biopsy, which would result in 60% unnecessary (negative) biopsies. 23 In Table 3 , the continuum of PC risk for different PSA ranges is presented as a result of the PCPT (Prostate Cancer Prevention Trial) and the European Randomised Study of Screening for Prostate Cancer (ERSPC). 22, 24 As shown, sensitivity decreases with the increasing PSA level, whereas specificity increases with the increasing PSA level. Consequently, decreasing PSA cutoff levels not only leads to a higher detection rate of PC but also leads to an increase in the diagnosis of cancers, which might otherwise never bother their carrier (potentially overdiagnosed cancers). 25 At present, the suggested PSA cutoff to biopsy a man for screening differs between 2.6 and 4.0 ng ml À1 . 18, 26, 27 Future data that include the comparison of the different studies with long follow-up might show the difference in mortality and morbidity outcomes using these different PSA thresholds. Although DRE is widely used for the diagnosis of PC, the value of DRE remains controversial in screening and early detection programs for PC. 28 The acceptability of the DRE test as a screening procedure seems to be less than PSA as the participation in a screening program with combined DRE and PSA was twice as low as with PSA alone.
18 Table 4 provides an overview of the positive-predictive value for DRE in the lower PSA ranges. According to Table 4 , DRE has a low sensitivity and predictive value in men with low PSA levels. [29] [30] [31] [32] [33] The positive-predictive value of DRE is limited to 4-19% at serum PSA levels below 3.0 ng ml
À1
. This proportion equals to the percentage of 15% cancers that were diagnosed in the study of Thompson et al., 22 in which they performed biopsies in all men with a PSA o4.0 ng ml À1 without using DRE. Therefore, the studies presented in Table 4 might have found a similar PC detection rate without the use of DRE in PSA levels of p3.0 ng ml
. Accordingly, it might be concluded that men with low PSA values have a 15% PC detection rate with or without the use of DRE, and that consequently, the additional value of the DRE is restricted in lower PSA ranges.
In contrast, several researchers still suggest that with the use of DRE, men will be screened more selectively. It is shown that men with a positive DRE are more likely to have high-grade PC than men with nonpalpable tumors. 34, 35 For this reason, the risk of omitting DRE, and therefore the omission of biopsies at PSA levels o2.6, o3.0 or o4.0 ng ml À1 , might be that potentially aggressive tumors at these low PSA levels remain undetected at screening. Catalona and colleagues 36 have confirmed this risk by showing that a substantial proportion of PCs detected by DRE at PSA levels o4.0 ng ml À1 have features associated with clinically aggressive tumors and that the omission of DRE from screening protocols might comprise treatment outcomes as omitting DRE at PSA levels o3.0 ng ml À1 would have detected 14% fewer PCs overall and 7% fewer PCs with a Gleason score of X7. In contrast, it is shown that screening without DRE at low PSA levels (PSA o3.0 ng ml À1 ) did not lead to the detection of significantly more (poorly differentiated) 
Complications of screening tests
The complications of PSA and DRE are limited, but prostate biopsies are related to clinical complications. 38, 39 These complications vary between studies as they depend on the antibiotic prophylaxis used, study population and the number of prostate biopsies performed. 38, 39 Djavan et al. 39 reported in their literature review, that included 11 prospective PC detection studies, hematuria and hematospermia in 12.5-58.4% and 5.1-50.5% of the procedures, respectively. In these same studies, rectal bleeding was reported in 2.8-37.1% of men, 1.4-4.2% of men reported fever after prostate biopsies, and 0-0.5% of men needed hospitalization because of symptoms of sepsis or prostatitis. 39 Overall, 0-1.2% of men reported urinary retention after prostate biopsies. 39 
Randomized control trials for PC screening
Two randomized control studies were designed to evaluate the effectives of screening ( Table 5 ). The ERSPC and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO trial) were designed to evaluate whether population-based screening reduces mortality caused by PC, with an acceptable level of quality-of-life aspects and the associated costs. 18, 27 The ERSPC trial is conducted in eight European countries (Belgium, Finland, France, Italy, The Netherlands, Spain, Sweden and Switzerland) and enrolled 267 994 men aged 55-74 years. All men with a previous diagnosis of PC were excluded. In the ERSPC trial, men were screened in most countries with an interval of 4 years; however, in Sweden, men were screened with an interval of 2 years. The screening algorithm differed among the study centers (Table 5) . [40] [41] [42] [43] [44] [45] [46] The PLCO is a trial conducted in the United States that enrolled 155 000 women and men, 55-74 years of age, in 10 screening centers. All men with a previous diagnosis of PC were excluded. In the PLCO trial, men in the intervention arm received annual screening by DRE and serum PSA determination (Table 5) . 27 
Results
Intermediate results of PC screening
In the ERSPC and PLCO trials, more men were diagnosed with PC in the intervention arm than in the control arm of the study. [47] [48] In the ERSPC trial, the cumulative incidence of PC was 8.2 and 4.8% for the intervention and control groups, respectively, after 9 years. 48 In the PLCO trial, PC was diagnosed in more subjects in the intervention group (7.3%) than in the control group (6.0%) at 7 years. 47 In the ERSPC and PLCO screening trials, a stage distribution was observed among men who were screened for PC. In the Rotterdam section of the ERSPC trial, after comparing the intervention arm with the control arm, a statistically significant migration to more favorable stages was observed in the intervention arm The implementation of screening for prostate cancer PJ van Leeuwen et al (Table 6 ). 49 In the screening population of the PLCO, the large majority of PCs were stage II at diagnosis, regardless of the mode of detection in the screening group. However, overall, the numbers of subjects with advanced (stage III or IV) tumors were statistically similar in the screening and control groups, with 122 men in the screening group and 135 men in the control group (Table 6) . 50 The reported interval cancers (those clinically diagnosed within a screening interval) in the ERSPC and PLCO trials were infrequent and in general with favorable characteristics. The ERSPC-Rotterdam reported 25 interval cancers that were diagnosed in the first 4 years after initial screening. In all, 7 of the 25 cancers were diagnosed in men who had refused a recommended biopsy at their initial screening. Of the To assess the usefulness of DRE as a stand-alone screening test in low PSA ranges, ERSPC-Rotterdam; N ¼ 10 523
The positive-predictive value of DRE in the lower PSA areas PSA PPV (%) 0.0-0.9 4 1.0-1.9 10 2.0-2.9 11 3.0-3.9 33 4.0-9.9 45 Yamamoto et al.
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To investigate the usefulness of DRE for prostate cancer diagnosis in subjects with PSA levels of p4.0 ng ml Bozeman et al.
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Men with abnormal DRE findings and a PSA level o4.0 ng ml À1 who underwent prostate biopsy to assess the positive-predictive value of DRE for men PSA o4.0 ng ml
The positive-predictive value of DRE for PSA o4.0 ng ml 18 cancers, all were classified as stage T1A-C or T2A, none were poorly differentiated or in a metastatic stage. 51 In the PLCO trial, 204 interval cancers were diagnosed. Of these cancers, 96.1% were classified as stage T1A-C or T2A and 2.0% were classified as stage IV disease. 50 
Final results of PC screening
Mortality data have been presented by the ERSPC and PLCO trials ( Table 7) . The ERSPC trial reported that PSA screening without DRE was associated with a 20% relative reduction in the death rate from PC at a median follow-up of 9 years. 52 The absolute reduction in the screening population was 7 PC deaths per 10 000 men who were screened. The results were associated with a number of 1410 men who needed to be screened and 48 men who needed treatment to save one death from PC. The treatment distributions were slightly different between the two groups, however, unlikely to have a major role in interpretation of the final results. 53 Data analysis of the ERSPC with adjustment for the diluting effect of nonattendance and contamination showed that the mortality effect among men increased to 30%. [54] [55] In the ERSPC trial, 82.2% of the men in the screening group were screened at least once and the average rate of compliance with biopsy recommendations was 85.8% (range, 65.4-90.3) . 48 The level of contamination by PSA testing in the control group was estimated in the order of 20-31%. 54, 56, 57 The PLCO trial found no mortality benefit from combined screening with PSA testing and DRE during a median follow-up of 7-10 years comparing those screened with those who were not. 47 The incidence of death per 10 000 person-years was 2.0 (50 deaths) in the screening group and 1.7 (44 deaths) in the control group (rate ratio (RR), 1.13; 95% confidence interval (95% CI): 0.75-1.70) after a median of 7 years follow-up. The data at 10 years were 67% complete and consistent with these overall findings. Treatment distributions were similar in both the groups within each tumor stage. 47 In the PLCO trial, compliance with the screening protocol overall was 85% for PSA testing and 86% for DRE. 47 The average rate of compliance with biopsy recommendations was 40%. The level of contamination is well established, that is, the rate of PSA testing was 40-52% and the rate of screening by DRE ranged from 41 to 46% in the control group. 47 No results are available for the effect of screening after the adjustment for the contamination; however, PC-specific mortality was 25% lower among the men who were screened before randomization in the PLCO trial. 47 Whereas the ERSPC found a statistically significant reduction in PC mortality with screening, the PLCO trial did not. In the PLCO trial, contamination in the control group and compliance with the screening protocol in The implementation of screening for prostate cancer PJ van Leeuwen et al the intervention group is of major influence. This is highlighted in the stage distribution among the men in the control arm of the PLCO study. In comparison with 96% of men diagnosed with a stage pII tumor in the intervention arm, 94.3% of men were diagnosed with a stage pII tumor in the control arm of the PLCO trial. Consequently, the PLCO trial is more a trial comparing two screening strategies of a different intensity and inadequate in establishing whether PC screening has the potential to reduce PC-specific mortality. Therefore, we can conclude that systematic PC screening is not effective in terms of reducing PC-specific mortality in comparison with widespread opportunistic screening and early detection. The ERSPC is a randomized controlled trial with an adequate methodological design, a high level of compliance in the intervention group and a relatively low level of contamination in the control group of the study. Furthermore, intention-to-screen analysis and analyses with adjustment for nonattendance and contamination are available. In essential, the ERSPC trial provides clear evidence that screening for PC has the potential to reduce PC-specific mortality.
Potential harms of PC screening
No large randomized study determined whether the detection of PC by mass screening improves the longterm health status and health-related quality of life. It is proven that screening increase PC incidence. 47, 48 The excess incidence and overtreatment are associated with a distinct pattern of change in quality of life. 58, 59 Quality-of-life parameters that are affected, are a change pattern in the urinary, bowel and erectile functions, as well as emotional distress and anxiety. 58, 59 Cost effectiveness of PC screening
No results from randomized controlled trials are reported on cost effectiveness, cost utility or cost benefit of screening for PC.
Mortality reduction of screening for breast, colorectal, lung and cervix cancer
Randomized controlled trials demonstrated contradictory results that mammographic screening reduces mortality from breast cancer. Two trials with adequate randomization did not show a significant reduction in breast cancer mortality, RR: 0.93 (95% CI: 0.80-1.09) at 13 years. 60 In contrast, four trials showed a significant reduction in breast cancer mortality, RR: 0.75 (95% CI: 0.67-0.83). 60 The RR for all six trials combined was 0.80 (95% CI: 0.73-0.88). 60 Data from prospective studies have found that the NNS (number needed to screen to save one death from prostate cancer) to save one breast cancer-specific death to be 1500 and the NNT (number needed to treat to save one death from prostate cancer) to save one cancer-specific death to be 10. [60] [61] [62] It has been established that breast screening is cost effective (Table 8) . 63 Screening for colorectal cancer is implemented in many European countries. 64 For colorectal cancer, screening data are available from four eligible randomized control trials showing that participants allocated to screening with fecal occult blood test had a 16% reduction in the relative risk of colorectal cancer mortality (RR: 0.84 (95% CI: 0.78-0.90)). 65 When adjusted for screening attendance in individual studies, there was a 25% relative risk reduction (RR 0.75, 95% CI: 0.66-0.84) for those attending at least one round of screening using the fecal occult blood test. 65, 66 The NNS to save one cancer-specific death would be in the order of 600 cases and the NNT in the order of 2 cases. 65, 67 Several studies have indicated that colorectal screening is cost effective (Table 8) . 68 Lung cancer screening using regular chest radiography and sputum examination programs were not effective in reducing mortality caused by lung cancer. Studies have shown that early detection of lung cancer was possible with such programs, but mortality was not improved. 69 At present, randomized control studies using computed tomography scan are ongoing for lung cancer in high-risk patients; however, results are not expected before 2010 (Table 8 ). No reduction --No RCT with chest radiography showed no reduction in mortality RCTs with computed tomography are ongoing Cervix cancer [71] [72] [73] Reduction between 5 and 80% --Yes No results RCT Mortality declined between 5 and 80% in 5 countries after the start of screening Abbreviations: CI, confidence interval; NNS, number needed to screen to save one death from cancer; NNT, number needed to treat to save one death from cancer; RCT, randomized controlled trial; RR, rate ratio.
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For cervical cancer, Cytological Papanicolaou (Pap) smear screening remains the best method readily available in reducing both incidence and mortality. No randomized controlled trials are performed, indicating that screening for cervical cancer reduces mortality. However, various studies (mainly time series and casecontrol) have shown that the widespread use of cervical screening in developed countries has been associated with the substantial reduction in mortality rate from cervical cancer. A study conducted in five northern European countries investigated the time trends in mortality from cervical cancer in relation to the extent and intensity of organized screening programs. In all five countries, the cumulative mortality rates (0-74 years) decreased by 80-85% between 1965 and 1982. 71 The NNS was in the order of 100-300 women. 72 The costeffectiveness studies concluded that cervical screening falls within the acceptable limits of cost effectiveness (Table 8) . 73 PC screening has, relative to screening for breast and colorectal cancer, a comparable impact on relative risk reduction in cancer-specific mortality. Nevertheless, the absolute benefit of PC screening is modest compared with screening for colorectal cancer. For this reason, compared with other colorectal cancer screening, a relatively high number of men would need PC screening to prevent one man from cancer-specific death. Finally, the additional number of men who are diagnosed with PC is large in comparison with breast and colorectal cancer screening. In this respect, the main limitation of PC screening is the difference in natural history of the disease and/or the lack of a screening test with high sensitivity and specificity for aggressive cancer. Finally, in comparison with screening for breast, cervical and colorectal cancer, no evidence is available that PC screening is cost effective.
Future perspectives of PC screening
Discussion regarding the introduction of PC screening consists of the lack in balance between the reduction in PC mortality and increase in PC incidence. The most valid PC screening study, the ERSPC, showed that screening has the potential to reduce PC mortality by 20%, whereas PC incidence increased by 70% after a median follow-up of 9 years. 48 In other words, screening reduces mortality, but as detection and treatment have increased costs and morbidity, many men diagnosed with indolent disease are labeled 'a false disease survivor' with likely an attendant emotional and financial burden. However, the results from the ERSPC trial are presented as cumulative values after a median of 9 years, and are likely to change after longer follow-up.
The percentage of 70% of men diagnosed with PC due to screening, in excess to the number of men who were diagnosed with PC in the absence of screening, is likely to reduce after longer follow-up. As the mean age of all men alive at end of the ERSPC study was 69 years, and the mean age of a PC diagnosis in the absence of PC screening is 71 years, more men will likely be diagnosed in the control arm of the ERSPC study in the following years. 74, 75 Furthermore, as most men participating in the screening arm of the ERSPC are over the age of cessation screening (that is, 69-74 years), less men will be diagnosed with PC in the intervention arm during the first following years. 48 Therefore, the 70% increase in PC incidence is likely to decrease after more years of observation. These prognoses are in line with the predicted overdiagnosis by the microsimulation program MISCAN, or Microsimulation Screening Analysis, which estimated a 50% overdiagnosis if screening would be introduced. 76 In addition, reduction in PC-specific mortality is likely to increase after more years of follow-up. These predictions are based on the same ERSPC data. The ERSPC trial showed that PC-specific mortality started to differ more than 7 years after the start of observation. In addition, after 9 years of observation, mortality rate increased more slowly in the intervention population than in the control population (Figure 1) . 48 On the basis of these trends, reduction in PC-specific mortality may increase with further follow-up, and the small benefits of screening will increase over time. Consequently, if this further reduction is achieved, the increased detection rate may be worthwhile.
Although further data from the screening studies might solve the main issue in the discussion regarding PC screening, studies seem to be warranted that optimize the screening protocols to minimize overdetection and overtreatment that are related to screening. A more selective approach to prostate biopsy using a personal risk-based strategy, rather than PSA alone, seems to have the potential to reduce this overdiagnosis. 77, 78 Therefore, screening programs should be more individualized with respect to prostate biopsy, the age of cessation screening and the interval between two screening rounds. Consequently, these screening tools should not depend on PSA alone, but on a multivariate risk strategy, including age, PSA, prostate volume, previous biopsies, medical history, etc. 78 Furthermore, the implementation of chemoprevention, with 5a-reductase inhibitors (5AR), might have the potential to reduce the excess incidence due to PC screening. 79 Two prospective clinical trials that evaluated the use of 5AR with PC prevention as a primary end 80 The REDUCE trial (REduction by DUtasteride of prostate Cancer Events) showed that PC incidence decreased by 23% in men who received the 5AR dutasteride in comparison with placebo after 4 years. 81 However, in contrast to the REDUCE trial that showed no increase in high-grade tumors with 5AR use, in the PCPT trial, the prevalence of high-grade tumors (Gleason score 7-10) on biopsy increased in the 5AR group (37.0% of all tumors) compared with the placebo group (22.2%; Po0.001).
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Although these unfavorable outcomes in the PCPT seems to be based on study biases (additional analysis has demonstrated finasteride to be safe and effective in reducing the risk of cancer regardless of risk stratum), the REDUCE trial has to provide additional data to solve this issue. [82] [83] [84] However, if, as the REDUCE trial showed, the incidence of PC with Gleason score 5-6 can be significantly reduced, and at the same time no increase in high-grade tumors with 5AR use will occur, chemoprevention might have the potential to reduce the detection of favorable indolent disease and the potential to make screening more profitable.
Conclusions
The essential difficulty of screening in general, and of PC screening in particular, was observed by Wilson and Jungner in 1968 when they stated that the central idea of early detection and treatment was essentially simple; however, that the path to its successful achievement (on the one hand, bringing treatment to those with previously undetected disease, and, on the other, avoiding harm to those individuals not in need of treatment) was far from simple. For this reason, 10 criteria that had to be satisfied before a screening program could be introduced were defined and updated recently. To date, the classic and updated criteria seem to be of essential value for PC screening policy decisions as the harms and benefits of PC screening seem to be hardly in balance.
On the basis of the presented evidence we conclude the following:
(1) PC is an important health problem. (2) PSA is the most accurate screening test currently available. (3) DRE has a limited positive-predictive value in men with a low PSA value and should not necessarily be recommended as a primary screening tool as it causes an unfavorable number of biopsies to detect one cancer in low PSA ranges. Furthermore, there is limited understanding of the natural history of PC, meaning that there is a lack in data regarding which specific PC will develop from an indolent to a significant disease and which PC will not surface clinically during lifetime if left undiagnosed and/or untreated. For these reasons, there is no agreed policy with regard to which men should be treated with aggressive curative treatment and which men might be treated by an expectant management to reduce overdiagnosis. Therefore, we have to conclude that there is no scientific basis for the introduction of a population-based PC screening program yet, as a number of essential criteria are not met. 8, [11] [12] [13] [14] [15] Later data of the ongoing randomized controlled trials are required to show the cumulative results after longer follow-up. Maybe the results may provide more evidence and a convenient balance between the screening harms and benefits, suggesting that population-based screening for PC might become less controversial or even justified in future.
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